Table 3.
Odds ratio of ACPA-positive RA, ACPA-negative RA according to duration of use among current and past PMH users, women aged 50–70
| Duration of PMH use (years)a | ACPA-status | PMH use | Ca/Co | OR 95 % CIb | OR 95 % CIc |
|---|---|---|---|---|---|
| 1–6 years | ACPA-positive | Ever | 38/147 | 0.8 (0.5–1.1) | 0.8 (0.5–1.2) |
| Current | 4/44 | 0.3 (0.1–0.7) | 0.3 (0.1–0.7)d | ||
| Past | 34/103 | 1.0 (0.6–1.5) | 1.0 (0.7–1.6) | ||
| Never | 209/626 | 1.0 | 1.0 | ||
| ACPA-negative | Ever | 25/147 | 1.0 (0.6–1.6) | 0.9 (0.6–1.5) | |
| Current | 3/44 | 0.4 (0.1–1.3) | 0.4 (0.1–1.3) | ||
| Past | 22/103 | 1.2 (0.7–2.1) | 1.2 (0.7–2.0) | ||
| Never | 109/626 | 1.0 | 1.0 | ||
| 7 years or more | ACPA-positive | Ever | 52/152 | 1.0 (0.7–1.5) | 1.0 (0.7–1.5) |
| Current | 18/59 | 0.9 (0.5–1.6) | 0.8 (0.5–1.5) | ||
| Past | 34/93 | 1.1 (0.7–1.7) | 1.1 (0.7–1.8) | ||
| Never | 209/626 | 1.0 | 1.0 | ||
| ACPA-negative | Ever | 29/152 | 1.2 (0.7–1.8) | 1.1 (0.7–1.7) | |
| Current | 15/59 | 1.5 (0.8–2.7) | 1.3 (0.7–2.4) | ||
| Past | 14/93 | 0.9 (0.5–1.7) | 0.9 (0.5–1.7) | ||
| Never | 109/626 | 1.0 | 1.0 |
EIRA, Sweden, 2006–2011
ACPA antibodies to citrullinated peptides antigens, RA rheumatoid arthritis, PMH postmenopausal hormone, Ca/Co number of cases/controls, OR odds ratio, CI confidence interval
aDuration of PMH use among those with available information
bAdjusted by age and residential area
cAdjusted by age, residential area and smoking (pack-years)
d p = 0.0095